- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patent holdings for IPC class A61P 31/00
Total number of patents in this class: 6545
10-year publication summary
|
173
|
278
|
369
|
320
|
418
|
411
|
408
|
332
|
278
|
77
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Mondobiotech Laboratories AG | 311 |
275 |
| Bristol-myers Squibb Company | 4821 |
65 |
| The Regents of the University of California | 20502 |
43 |
| Centre National de La Recherche Scientifique | 10856 |
34 |
| Merck Patent GmbH | 5723 |
26 |
| Agency for Science, Technology and Research | 3684 |
26 |
| The Johns Hopkins University | 5798 |
24 |
| Boehringer Ingelheim International GmbH | 4567 |
22 |
| The General Hospital Corporation | 4808 |
22 |
| Novartis AG | 10420 |
21 |
| F. Hoffmann-La Roche AG | 7847 |
21 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3348 |
21 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3114 |
21 |
| The University of North Carolina at Chapel Hill | 2076 |
21 |
| Pfizer Inc. | 3389 |
20 |
| President and Fellows of Harvard College | 6068 |
20 |
| Takeda Pharmaceutical Company Limited | 2726 |
20 |
| Merck Sharp & Dohme Corp. | 2185 |
18 |
| AstraZeneca AB | 2832 |
17 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2965 |
17 |
| Other owners | 5791 |